People with type 2 diabetes who use SGLT2 inhibitors have a lower risk of major adverse cardiovascular events (MACE) compared with people who use DPP-4 inhibitors a major observational study has found. Published in the BMJ, the Canadian retrospective study compared outcomes after almost one year of follow up for more than 200,000 patients taking ...
SGLT-2 inhibitors offer more short term cardioprotective benefit compared to DPP-4 inhibitors
By Michael Woodhead
24 Sep 2020